# US 2004/0202999 A1 · Conditionally replicating viral vectors and their use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0202999 A1
- Document ID: US20040202999A1
- Status: Published application
- Kind: A1
- Application number: 10/841,291
- Filed: 2004-05-07
- Published: 2004-10-14
- Earliest claimed: 1995-11-28
- Assignees: The Johns Hopkins University School of Medicine
- Inventors: Boro Dropulic; Paula M. Pitha
- Web page: https://patentgrep.com/patent/US20040202999A1

## CPC

- C12N 15/1132: {against retroviridae, e.g. HIV}
- C12N 15/86: Viral vectors
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C12N 2740/16043: viral genome or elements thereof as genetic vector
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention provides a conditionally replicating viral vector, methods of making, modifying, propagating and selectively packaging, and using such a vector, isolated molecules of specified nucleotide and amino acid sequences relevant to such vectors, a pharmaceutical composition and a host cell comprising such a vector, the use of such a host cell to screen drugs. The methods include the prophylactic and therapeutic treatment of viral infection, in particular HIV infection, and, thus, are also directed to viral vaccines and the treatment of cancer, in particular cancer of viral etiology. Other methods include the use of such conditionally replicating viral vectors in gene therapy and other applications.

## Claims

### Claim 1

A retroviral vector comprising:
(a) 5′ and 3′ long terminal repeats (LTRs) derived from a lentivirus, wherein the 5′ LTR is modified to comprise sequences that are not derived from said lentivirus whereby control of expression by said modified 5′ LTR differs from control of expression by an unmodified LTR; and
(b) a heterologous nucleic acid sequence operably linked 3′ of the 5′ LTR to permit control of its expression by the 5′ LTR; and
wherein said 3′ LTR is downstream of the heterologous sequence.

### Claim 2 (depends on 1)

The retroviral vector of claim 1, wherein the lentivirus is human immunodeficiency virus-1 (HIV-1) or human immunodeficiency virus-2 (HIV-2).

### Claim 3 (depends on 1)

The retroviral vector of claim 1, wherein the vector conditionally replicates.

### Claim 4 (depends on 3)

The retroviral vector of claim 3, wherein the vector is a conditionally replicating human immunodeficiency virus (crHIV) vector.

### Claim 5 (depends on 1)

The vector of claim 1, wherein the 5′ LTR region comprises a promoter and/or enhancer that is not derived from said lentivirus.

### Claim 6 (depends on 5)

The vector of claim 5, wherein the enhancer is a silencer.

### Claim 7 (depends on 5)

The vector of claim 5, wherein the promoter and/or enhancer responds to a cytokine.

### Claim 8 (depends on 7)

The vector of claim 7, wherein the response comprises an increase in transcription from the promoter.

### Claim 9 (depends on 7)

The vector of claim 7, wherein the response comprises a decrease in transcription from the promoter.

### Claim 10 (depends on 7)

The vector of claim 7, wherein the cytokine is selected from the group consisting of interleukins, lymphokines, monokines, interferons, colony stimulating factors, and chemokines.

### Claim 11 (depends on 10)

The vector of claim 10, wherein the cytokine is selected from the group consisting of IL-2, tumor necrosis factor α, and RANTES.

### Claim 12 (depends on 5)

The vector of claim 5, wherein the promoter and/or enhancer is macrophage-specific.

### Claim 13 (depends on 5)

The vector of claim 5, wherein the promoter and/or enhancer is tumor-specific.

### Claim 14 (depends on 5)

The vector of claim 5, wherein the promoter responds to a DNA binding protein.

### Claim 15 (depends on 1)

The vector of claim 1, wherein the heterologous nucleic acid sequence is a sequence transcribed to an RNA selected from the group consisting of an antisense molecule, an RNA decoy, and a ribozyme, or the heterologous nucleic acid sequence encodes a protein selected from the group consisting of a transdominant mutant, a toxin, and a single-chain antibody (scAb) directed to a viral structural protein.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

A host cell comprising the vector of any of claims 1-15.

### Claim 17 (depends on 7)

A host cell comprising the vector of claim 7, wherein said cell further comprises a cytokine that is native to the cell.

### Claim 18 (depends on 7)

A host cell comprising the vector of claim 7, wherein said cell further comprises a cytokine that is provided to the cell.

### Claim 19 (depends on 18)

The host cell of claim 18, wherein the cytokine is provided to the cell by a second vector.

### Claim 20 (depends on 16)

A method for cell specific replication and/or propagation of a retroviral vector, said method comprising culturing the host cell of claim 16.

### Claim 21 (depends on 16)

A method to express a heterologous nucleic acid sequence in a specific cell comprising culturing the cells of claim 16.

### Claim 22 (depends on 17)

A method to express a heterologous nucleic acid sequence in a specific cell comprising culturing the cells of claim 17.

### Claim 23 (depends on 18)

A method to express a heterologous nucleic acid sequence in a specific cell comprising culturing the cells of claim 18.

### Claim 24 (depends on 19)

A method to express a heterologous nucleic acid sequence in a specific cell comprising culturing the cells of claim 19.

### Claim 25 (depends on 1)

The vector of claim 1, which lacks a nucleotide sequence encoding Tat.

### Claim 26 (depends on 25)

A recombinant host cell which contains the vector of claim 25.

### Claim 27 (depends on 26)

A method to express a heterologous nucleic acid sequence in a specific cell comprising contacting the cell of claim 26 with a helper vector comprising a nucleotide sequence encoding Tat, operably linked to a promoter for its expression.

### Claim 28 (depends on 27)

The method of claim 27, wherein the lentivirus is human immunodeficiency virus-1 (HIV-1) or human immunodeficiency virus-2 (HIV-2).

### Claim 29 (depends on 25)

The vector of claim 25, wherein the vector conditionally replicates.

### Claim 30 (depends on 29)

The vector of claim 29, wherein the vector is a conditionally replicating human immunodeficiency virus (crHIV) vector.

### Claim 31 (depends on 25)

The vector of claim 25, wherein the promoter and/or enhancer is macrophage-specific.

### Claim 32 (depends on 25)

The vector of claim 25, wherein the promoter and/or enhancer is tumor-specific.

### Claim 33 (depends on 20)

The method of claim 20, wherein the heterologous nucleic acid sequence is a sequence transcribed to an RNA selected from the group consisting of an antisense molecule, an RNA decoy, and a ribozyme, or the heterologous nucleic acid sequence encodes a protein selected from the group consisting of a transdominant mutant, a toxin, and a single-chain antibody (scAb) directed to a viral structural protein.

### Claim 34

A method of secreting an antibody in a cell comprising:
(a) contacting a cell with a helper vector comprising a promoter and/or enhancer that can be activated by a cellular factor present in the cell; and
(b) contacting the cell with a retroviral vector comprising 5′ and 3′ long terminal repeats (LTRs) derived from a lentivirus, and a heterologous nucleic acid sequence operably linked 3′ of the 5′ LTR to permit its expression by the 5′ LTR, wherein said heterologous sequence encodes an antibody that is secreted and that acts upon the cellular factor, and wherein said 3′ LTR is downstream of the heterologous sequence.

### Claim 35 (depends on 34)

The method of claim 34, wherein the lentivirus is human immunodeficiency virus-1 (HIV-1) or human immunodeficiency virus-2 (HIV-2).

### Claim 36 (depends on 34)

The method of claim 34, wherein the vector conditionally replicates.

### Claim 37 (depends on 36)

The method of claim 36, wherein the vector is a conditionally replicating human immunodeficiency virus (crHIV) vector.

### Claim 38 (depends on 34)

The method of claim 34, wherein the cellular factor is selected from the group consisting of a bacteria, a cytokine, an antibiotic, and a toxin.

### Claim 39 (depends on 34)

The method of claim 34, wherein the heterologous sequence encodes an antibody selected from the group consisting of an anti-bacterial, anti-toxin, and anti-pathogenic antibody.

### Claim 40

A retroviral vector comprising:
(a) 5′ and 3′ long terminal repeats (LTRs) derived from a lentivirus, wherein the 5′ LTR comprises a promoter and/or enhancer that is responsive to a cellular factor; and
(b) a heterologous nucleic acid sequence operably linked 3′ of the 5′ LTR to permit its expression by the 5′ LTR, wherein said heterologous sequence encodes an antibody that acts upon the cellular factor and wherein the 3′ LTR is downstream of the heterologous sequence.

### Claim 41 (depends on 40)

The retroviral vector of claim 40, wherein the lentivirus is human immunodeficiency virus-1 (HIV-1) or human immunodeficiency virus-2 (HIV-2).

### Claim 42 (depends on 40)

The retroviral vector of claim 40, wherein the vector conditionally replicates.

### Claim 43 (depends on 42)

The retroviral vector of claim 42, wherein the vector is a conditionally replicating human immunodeficiency virus (crHIV) vector.

### Claim 44 (depends on 40)

The vector of claim 40, wherein the cellular factor is selected from the group consisting of a bacteria, a cytokine, an antibiotic, and a toxin.

### Claim 45 (depends on 40)

The vector of claim 40, wherein the heterologous sequence encodes an antibody selected from the group consisting of an anti-bacterial, anti-toxin, and anti-pathogenic antibody.

### Claim 46 (depends on 40)

The vector of claim 40, wherein the promoter is a tet promoter, a toxin responsive sequence, or a cytokine responsive promoter.

### Claim 47

A retroviral vector comprising
(a) 5′ and 3′ long terminal repeats (LTRs) derived from a retrovirus, wherein the 5′ LTR comprises sequences that are not derived from said retrovirus; and
(c) a heterologous nucleic acid sequence operably linked 3′ of the 5′ LTR to permit its expression by the 5′ LTR, wherein said heterologous nucleic acid sequence is a genetic antiviral agent that is a siRNA and wherein the 3′ LTR is downstream of the heterologous sequence.

### Claim 48

A method of expressing a heterologous nucleic acid sequence in a specific cell comprising
(a) contacting said cell with a retroviral vector comprising 5′ and 3′ long terminal repeats (LTRs) derived from a retrovirus, a heterologous nucleic acid sequence operably linked 3′ of the 5′ LTR to permit its expression by the 5′ LTR, wherein said heterologous nucleic acid sequence is a genetic antiviral agent that is a siRNA, wherein the 3′ LTR is downstream of the heterologous sequence, and lacking a nucleotide sequence encoding Tat, and
(b) contacting said cell with a helper vector comprising a nucleotide sequence encoding Tat, and a cell specific promoter and/or enhancer that is capable of driving the expression of the Tat gene.
